Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Biogen Canada
New Progress Toward Public Reimbursement of SKYCLARYS™ for People Living with Friedreich Ataxia in Quebec
Member News June 8, 2026 Biogen Canada INESSS reassessment supports the therapeutic value of SKYCLARYS and advances the reimbursement pathway for eligible patients in Quebec.
Eisai Maintains Commitment to People Living with Early Alzheimer’s Disease Despite CDA-AMC Draft Recommendation: Patients Deserve Access to Effective Treatment - Life Sciences British Columbia
Member News February 19, 2026 Biogen Canada Decision overlooks compelling evidence that LEQEMBI ® (lecanemab-irmb) meaningfully slows the progression of Alzheimer’s disease and preserves ability to perform activities of daily living for those in the early stages of disease. MISSISSAUGA and TORONTO, ON – Eisai Limited and Biogen Canada Inc. are disappointed by and disagree with Canada’s Drug Agency (CDA-AMC) that the Agency will not recommend LEQEMBI® for public reimbursement in Canada.
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada - Life Sciences British Columbia
Member News December 9, 2025 Biogen Canada Postpartum depression (PPD) affects up to one in five Canadian women1; it is the most common complication2 related to childbearing and a leading cause of maternal death in Canada3 Left untreated, PPD can have short- and long-term consequences on maternal health, child development and family well-being4,5,6 ZURZUVAE is a 14-day, oral single course of treatment that offers relief from depressive symptoms as early as Day 3, a significant step forward...
Health Canada Grants Authorization for LEQEMBI® (lecanemab) for the Treatment of Early Alzheimer's Disease
Member News October 27, 2025 Biogen Canada In Canada, LEQEMBI® is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes and who have confirmed amyloid pathology MISSISSAUGA and TORONTO, ON – and Biogen Canada Inc.
CDA Issues Positive Reimbursement Recommendation for SKYCLARYS™ (omaveloxolone), the Only Health Canada-Approved Treatment for Managing Friedreich Ataxia - Life Sciences British Columbia
TORONTO, ON – Biogen Canada Inc.is pleased to announce a significant step forward for Canadians living with Friedreich ataxia (FA), with the positive reimbursement recommendation by the Canada Drug Agency (CDA) Canadian Drug Expert Committee (CDEC) for SKYCLARYS™ (omaveloxolone) as a treatment for patients 16 years of age and older who meet certain criteria.1 This milestone brings Canadians outside Quebec affected by this rare neurodegenerative disease a step closer to accessing the only...
SKYCLARYS™ (omaveloxolone) Approval by Health Canada Ushers in a New Era for Friedreich’s Ataxia Treatment in Canada
Member News March 17, 2025 Biogen Canada As the only approved treatment to address disease progression, SKYCLARYS addresses a long-standing gap in the care of Canadians living with Friedreich’s ataxia Friedreich’s ataxia is a rare, progressive, debilitating and life-shortening neurodegenerative disease1 The approval of SKYCLARYS reflects Biogen’s commitment to pioneering innovation in rare diseases, driving progress in patient care, and addressing critical unmet needs TORONTO, ON – Biogen...
QALSODY™ (tofersen injection) Receives Conditional Marketing Authorization from Health Canada as the First ALS Treatment Targeting a Genetic Cause Original
QALSODY targets the root cause of SOD1-ALS, an ultra-rare and uniformly fatal neurodegenerative disease marked by motor neuron loss in the brain and spinal cord1 Biogen's second rare disease therapy to be approved in Canada reflects a continued commitment to advancing innovative therapies for diseases with high unmet medical need , /CNW/ - Biogen Canada Inc.
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Member News January 26, 2025 Biogen Canada Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer’s disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy TOKYO, JP & CAMBRIDGE, MA – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc.
Health Canada Accepts for Review New Drug Submission for Tofersen for Treatment of Rare, Genetic Form of ALS Original
SOD1- ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS that represents approximately two percent of all ALS cases1 Health Canada regulatory decision on tofersen New Drug Submission expected in early 2025 , /CNW/ - Biogen Canada Inc. announced today that Health Canada has accepted for review a New Drug Submission(NDS) for tofersen for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.
Confounder Adjustment Using the Disease Risk Score: A Proposal for Weighting Methods
Propensity score analysis is a common approach to addressing confounding in non-randomized studies. Its implementation, however, requires important assumptions (e.g., positivity). The disease risk score is an alternative confounding score that can relax some of these assumptions. Like the propensity score, the disease risk score summarizes multiple confounders into a single score, on which conditioning by matching allows the estimation of causal effects.
Public reimbursement for biosimilar BYOOVIZ™ to treat serious retinal disorders now secured in four provinces and two national benefits programs Original
Ontario and New Brunswick among latest jurisdictions to reimburse biosimilar of anti-VEGF ranibizumab, improving patient access to treatment for certain retinal diseases , /CNW/ - Biogen Canada Inc. is pleased to announce that Ontario, New Brunswick, and Prince Edward Island have joined Quebec to reimburse PrBYOOVIZ™ (ranibizumab injection), an anti-vascular endothelial growth factor (anti-VEGF) biosimilar therapy for certain eye conditions affecting the retina.
Biosimilar BYOOVIZ™ now reimbursed in Quebec to treat serious retinal disorders Original
First provincial listing of anti-VEGF ranibizumab biosimilar brings cost-effective new option to patients and helps support healthcare system sustainability , /CNW/ - Biogen Canada Inc. is pleased to announce that Quebec has become the first province to reimburse PrBYOOVIZ™ (ranibizumab injection), an anti-vascular endothelial growth factor (anti-VEGF) biosimilar therapy for certain eye conditions affecting the retina.
PrBYOOVIZ™, first PrLUCENTIS® biosimilar, now available in Canada to treat debilitating retinal disorders Original
Arrival of PrBYOOVIZ™ provides new, sustainable treatment option for Canadians with serious eye disorders that can lead to irreversible vision loss BYOOVIZ brings biosimilar science and the recognized efficacy of reference product PrLUCENTIS® to retinal vascular disorders , /CNW/ - Biogen Canada Inc.
Canadian-made video game designed to help maintain abilities and quality of life for children with rare, degenerative neuromuscular disease Original
Free, web-based game, Cloud Bazaar, promotes physical exercise in children with spinal muscular atrophy (SMA), a rare and degenerative neuromuscular disease. Game targets need for increased therapeutic exercise adherence in pediatric SMA patients by gamifying physical activities and making them more fun. Uses motion capture technology to track players' movements and responds with exercises that progressively challenge them according to their level of ability.
CADTH Ruling on SPINRAZA™ (nusinersen) Extinguishes Hope for Adults Needing Treatment for Spinal Muscular Atrophy (SMA) Original
CADTH recommends against reimbursement and access to potentially life-altering treatment for adult SMA patients, discounting the large body of real-world evidence of SPINRAZA's safety and effectiveness across age groups Provinces to ultimately decide on CADTH's reimbursement recommendation and the fate of adult patients living with this progressive, neurodegenerative rare disease Quebec leads by example as the only province that commits to funding SMA treatment for all patients, regardless of...
Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (Ranibizumab)
BYOOVIZ™ becomes the first Lucentis® biosimilar to be approved in Canada following its approval in Europe and the United States in 2021 INCHEON, Korea and TORONTO, March 10, 2022 /CNW/ - Samsung Bioepis Co., Ltd., and Biogen Canada Inc.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Biogen
Contact Biogen, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack